Immunocore Stock Analysis

IMCR
 Stock
  

USD 57.91  2.67  4.41%   

The latest price spike of Immunocore Holdings may raise some interest from retail investors. The stock closed today at a share price of 57.91 on 184,652 in trading volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.58. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Immunocore Holdings partners.
Please see Risk vs Return Analysis.
  
The Immunocore Holdings stock analysis report makes it easy to digest most publicly released information about Immunocore Holdings and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Immunocore Stock analysis module also helps to analyze the Immunocore Holdings price relationship with some important fundamental indicators such as market cap and management efficiency.

Immunocore Stock Analysis Notes

About 21.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.31. Immunocore Holdings had not issued any dividends in recent years. Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Immunocore Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people. To learn more about Immunocore Holdings call Bahija Jallal at 44 12 3543 8600 or check out https://www.immunocore.com.

Immunocore Holdings Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunocore Holdings' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunocore Holdings or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunocore Holdings has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 26.52 M. Net Loss for the year was (131.52 M) with loss before overhead, payroll, taxes, and interest of (46.71 M).
Immunocore Holdings currently holds about 208.06 M in cash with (96.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.74.
Roughly 59.0% of the company shares are owned by institutional investors

Immunocore Holdings Upcoming and Recent Events

Earnings reports are used by Immunocore Holdings to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunocore Holdings previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of March 2022
Next Financial Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Immunocore Largest EPS Surprises

Earnings surprises can significantly impact Immunocore Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-10
2021-09-30-62.65-69-6.3510 
2021-05-12
2021-03-31-58.61-66.48-7.8713 
2022-03-03
2021-12-31-82.21-91-8.7910 
View All Earnings Estimates

Immunocore Holdings SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunocore Holdings prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunocore Holdings investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunocore Holdings specific information freely available to individual and institutional investors to make a timely investment decision.
9th of September 2022
Other Events
View
7th of September 2022
Unclassified Corporate Event
View
10th of August 2022
Other Events
View
21st of July 2022
Unclassified Corporate Event
View
20th of July 2022
Other Events. Unclassified Corporate Event
View
11th of July 2022
Other Events
View
27th of June 2022
Other Events
View
9th of June 2022
Other Events
View

Immunocore Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunocore Holdings is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunocore Holdings backward and forwards among themselves. Immunocore Holdings' institutional investor refers to the entity that pools money to purchase Immunocore Holdings' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares3.9 K144 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares3.9 K116 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares3.9 K132 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares3.9 K143 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares3.9 K151 K
Zimmer Partners LpCommon Shares10 K426 K
Wells Fargo CompanyCommon Shares43620 K
Note, although Immunocore Holdings' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunocore Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunocore Holdings's market, we take the total number of its shares issued and multiply it by Immunocore Holdings's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Immunocore Profitablity

Immunocore Holdings' profitability indicators refer to fundamental financial ratios that showcase Immunocore Holdings' ability to generate income relative to its revenue or operating costs. If, let's say, Immunocore Holdings is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunocore Holdings' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunocore Holdings' profitability requires more research than a typical breakdown of Immunocore Holdings' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.54) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.01.

Management Efficiency

The entity has return on total asset (ROA) of (0.0885) % which means that it has lost $0.0885 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.2231) %, meaning that it created substantial loss on money invested by shareholders. Immunocore Holdings management efficiency ratios could be used to measure how well immunocore holdings manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 5th of December, Immunocore Holdings retains the Risk Adjusted Performance of 0.109, downside deviation of 5.23, and Market Risk Adjusted Performance of 1.26. Immunocore Holdings technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Immunocore Holdings, which can be compared to its competitors. Please check out Immunocore Holdings coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Immunocore Holdings is priced fairly, providing market reflects its last-minute price of 57.91 per share. Given that Immunocore Holdings has jensen alpha of 0.28, we strongly advise you to confirm Immunocore Holdings's regular market performance to make sure the company can sustain itself at a future point.

Immunocore Holdings Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immunocore Holdings middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immunocore Holdings. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Immunocore Holdings Predictive Daily Indicators

Immunocore Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunocore Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Immunocore Holdings Forecast Models

Immunocore Holdings time-series forecasting models is one of many Immunocore Holdings' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunocore Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Immunocore Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunocore Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunocore shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Immunocore Holdings. By using and applying Immunocore Stock analysis, traders can create a robust methodology for identifying Immunocore entry and exit points for their positions.
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Immunocore Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people.

Current Immunocore Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunocore analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunocore analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
51.33Strong Buy3Odds
Immunocore Holdings current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunocore analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunocore stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunocore Holdings, talking to its executives and customers, or listening to Immunocore conference calls.
Immunocore Analyst Advice Details

Immunocore Stock Analysis Indicators

Immunocore Holdings stock analysis indicators help investors evaluate how Immunocore Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunocore Holdings shares will generate the highest return on investment. By understating and applying Immunocore Holdings stock analysis, traders can identify Immunocore Holdings position entry and exit signals to maximize returns.
Begin Period Cash Flow129716000.00
Common Stock Shares Outstanding42488579.00
Total Stockholder Equity171547000.00
DescriptionImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase III dose escalation tr
Total Cashflows From Investing Activities-367000.00
Tax Provision-9405000.00
Property Plant And Equipment Net31537000.00
Retained Earnings-481392000.00
Cash And Short Term Investments237886000.00
Cash237886000.00
CodeIMCR
Accounts Payable7499000.00
Net Debt-174050000.00
50 Day M A54.0578
Total Current Liabilities61180000.00
Currency CodeUSD
Other Operating Expenses161610000.00
Non Current Assets Total39047000.00
Non Currrent Assets Other4770000.00
Please see Risk vs Return Analysis. Note that the Immunocore Holdings information on this page should be used as a complementary analysis to other Immunocore Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Immunocore Stock analysis

When running Immunocore Holdings price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Immunocore Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunocore Holdings. If investors know Immunocore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunocore Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
2.9 B
Quarterly Revenue Growth YOY
5.96
Return On Assets
(0.09) 
Return On Equity
(0.22) 
The market value of Immunocore Holdings is measured differently than its book value, which is the value of Immunocore that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocore Holdings' value that differs from its market value or its book value, called intrinsic value, which is Immunocore Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocore Holdings' market value can be influenced by many factors that don't directly affect Immunocore Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocore Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunocore Holdings value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocore Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.